Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak

Three new models for investigating mpox infection and pathogenesis identified

Tonix is advancing TNX-801, a live, attenuated, minimally replicative investigational vaccine candidate based on horsepox virus to protect against mpox disease

BERKELEY HEIGHTS, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today announced the publication of a paper, "Monkeypox virus clade IIb isolate exhibits reduced virulence relative to clade IIa isolates in multiple murine models," in the Journal of Virology, the peer-reviewed publication of the American Society for Microbiology (ASM). The research, conducted at Tonix, found new animal models for investigating mpox pathogenesis and demonstrated significant differences in virulence between the clade IIb circulating in the U.S. and the historic 2003 clade IIa.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.